Filing Flows › Comparisons › PAHC vs SRPT
Phibro Animal Health vs Sarepta Therapeutics: PAHC and SRPT compared
Phibro Animal Health is the larger company: $387M of revenue in its latest quarter (Q1 FY27) against $381M for Sarepta Therapeutics (Q3 2026). Phibro Animal Health is growing faster (+6% against -4% a year earlier). Phibro Animal Health is more profitable, with an operating margin of 12.8% against -2.4%.
Where the money goes: PAHC and SRPT
Phibro Animal Health (PAHC) · Q1 FY27
Phibro Animal Health, Q1 FY27: revenue $387M (+6% year over year), operating margin 12.8%, net earnings $29.5M, operating cash flow $26.1M. The chart follows the revenue to costs, profit and cash.
Sarepta Therapeutics (SRPT) · Q3 2026
Sarepta Therapeutics, Q3 2026: revenue $381M (-4% year over year), operating margin -2.4%, net loss $28.5M, operating cash flow $60.0M. The chart follows the revenue to costs, profit and cash.
| Phibro Animal Health (PAHC) | Sarepta Therapeutics (SRPT) | |
|---|---|---|
| Latest quarter | Q1 FY27 | Q3 2026 |
| Revenue | $387M | $381M |
| Revenue growth, Y/Y | +6% | -4% |
| Gross margin | 33.2% | — |
| Operating margin | 12.8% | -2.4% |
| Net earnings | $29.5M | −$28.5M |
| Net margin | 7.6% | -7.5% |
| Operating cash flow | $26.1M | $60.0M |
| Free cash flow | $7.3M | $57.0M |
| Market value | $1.3B | $1.9B |
| P/E | 13.2× | — |
| Analysts’ mean target | $47.00 | $21.68 |
Where the revenue comes from
Phibro Animal Health
- Animal Health: $293M (76%)
- Mineral Nutrition: $73.6M (19%)
- Performance Products: $20.2M (5%)
Sarepta Therapeutics
- Pmo Products: $240M (63%)
- Elevidys: $83.5M (22%)
- Other revenues: $57.6M (15%)
Questions
Which is bigger, Phibro Animal Health or Sarepta Therapeutics?
Phibro Animal Health is the larger company: $387M of revenue in its latest quarter (Q1 FY27) against $381M for Sarepta Therapeutics (Q3 2026).
Is Phibro Animal Health or Sarepta Therapeutics growing faster?
Phibro Animal Health is growing faster (+6% against -4% a year earlier).
Which is more profitable, Phibro Animal Health or Sarepta Therapeutics?
Phibro Animal Health is more profitable, with an operating margin of 12.8% against -2.4%.
More: Phibro Animal Health earnings · how Phibro Animal Health makes money · Sarepta Therapeutics earnings · how Sarepta Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.